Delivery included to the United States

Resistance of Cancer Cells to CTL-Mediated Immunotherapy

Resistance of Cancer Cells to CTL-Mediated Immunotherapy - Resistance to Targeted Anti-Cancer Therapeutics

Softcover reprint of the original 1st Edition 2015

Paperback (17 Oct 2016)

Save $4.82

  • RRP $162.85
  • $158.03
Add to basket

Includes delivery to the United States

10+ copies available online - Usually dispatched within 7 days

Other formats & editions

New
Hardback (30 Jun 2015) - 2015 $142.03

Publisher's Synopsis

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

Book information

ISBN: 9783319380674
Publisher: Springer International Publishing
Imprint: Springer
Pub date:
Edition: Softcover reprint of the original 1st Edition 2015
Language: English
Number of pages: 353
Weight: 6363g
Height: 235mm
Width: 155mm